What type of glioma is suggested by a TP53 mutation with PIK3CA amplification and wild-type BRAF, CDKN2A, EGFR, IDH1, and IDH2?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IDH-Wildtype Glioblastoma, WHO Grade 4

This molecular profile is most consistent with an IDH-wildtype glioblastoma (WHO grade 4), representing the most common and aggressive primary brain tumor in adults. 1

Molecular Reasoning

The key diagnostic features pointing to IDH-wildtype glioblastoma include:

Defining Characteristics Present:

  • Wild-type IDH1/IDH2: The absence of IDH mutations is the primary distinguishing feature that separates this from lower-grade astrocytomas and oligodendrogliomas 1
  • TP53 mutation: Present in approximately 25-30% of IDH-wildtype glioblastomas, though more commonly associated with IDH-mutant astrocytomas 2, 3
  • PIK3CA amplification: Occurs in IDH-wildtype glioblastomas as part of the receptor tyrosine kinase/PI3K/AKT pathway dysregulation 2

Key Exclusions:

  • No EGFR amplification: While EGFR amplification occurs in 40-50% of IDH-wildtype glioblastomas, its absence does not exclude the diagnosis 1
  • No CDKN2A deletion: Homozygous CDKN2A/B deletion is a marker of WHO grade 4 but is not required for diagnosis 1
  • No BRAF mutation: Excludes BRAF-driven low-grade gliomas and glioneuronal tumors 1

Diagnostic Algorithm

According to EANO guidelines, IDH-wildtype glioblastomas are classified based on:

  1. Histological features: Presence of necrosis and/or microvascular proliferation automatically qualifies as WHO grade 4 1

  2. In the absence of these histological features, evaluate for glioblastoma-associated molecular alterations:

    • EGFR amplification
    • TERT promoter mutations
    • +7/-10 cytogenetic signature

    If one or more of these alterations is present, classify as IDH-wildtype glioblastoma even without necrosis or microvascular proliferation 1

Important Caveats

The TP53 + PIK3CA Pattern:

This combination is somewhat atypical for classic IDH-wildtype glioblastoma. Research shows that among glioblastomas with TP53 mutations, 52% have concurrent mutations in actionable genes, with PIK3CA mutations occurring in approximately 4-11% 2. This molecular signature may represent:

  • A less common molecular subtype of IDH-wildtype glioblastoma
  • Potentially younger patient age at presentation 1
  • Possible alternative telomere maintenance mechanism given the absence of TERT promoter mutation (if tested) 4

Critical Additional Testing Needed:

To complete the molecular diagnosis, you should evaluate:

  1. TERT promoter mutation status: Present in ~70% of IDH-wildtype glioblastomas and is a molecular marker of WHO grade 4 1
  2. +7/-10 cytogenetic signature: Gain of chromosome 7 with loss of chromosome 10 is a defining molecular marker 1
  3. Histological grade: Presence of necrosis or microvascular proliferation
  4. ATRX status: Loss would be unusual in IDH-wildtype tumors and might suggest reconsideration of IDH testing 1

Differential Considerations:

If this tumor lacks the typical glioblastoma-associated alterations (EGFR amplification, TERT promoter mutation, +7/-10 signature) and shows no necrosis or microvascular proliferation, it may represent an IDH-wildtype diffuse astrocytoma requiring further molecular assessment, particularly in younger patients 1. However, the presence of TP53 mutation with PIK3CA amplification in an adult patient still favors IDH-wildtype glioblastoma.

Clinical Implications:

The absence of EGFR amplification and presence of PIK3CA alterations may have therapeutic relevance for clinical trial eligibility targeting the PI3K/AKT/mTOR pathway 5. The TP53 mutation may confer resistance to certain therapies and is associated with poorer outcomes even within IDH-wildtype glioblastomas 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.